Pasithea Therapeutics Corp. (KTTA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 200K 400K 600K Q4 '22: 486.6K Q4 '22

Gross Profit TTM

0 150K 300K 450K Q4 '22: 373.4K Q4 '22

Operating Income TTM

-27M -18M -9M 0 9M 18M 27M Q3 '21: -2.6M Q4 '21: -4.5M Q1 '22: -6M Q2 '22: -7.9M Q3 '22: -10.5M Q4 '22: -12.6M Q1 '23: -13.7M Q2 '23: -14.9M Q3 '23: -14.9M Q4 '23: -16M Q1 '24: -16.8M Q2 '24: -16.9M Q3 '24: -16.1M Q4 '24: -14.2M Q1 '25: -13.9M Q2 '25: -13.8M Q3 '25: -13.9M Q4 '25: -20.9M Q1 '26: -22.1M Q2 '26: -24M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-24M -16M -8M 0 8M 16M 24M Q2 '21: -1.3M Q3 '21: -2.8M Q4 '21: -2.2M Q1 '22: -3.2M Q2 '22: -5.1M Q3 '22: -8.2M Q4 '22: -13.9M Q1 '23: -15.9M Q2 '23: -17M Q3 '23: -16M Q4 '23: -16M Q1 '24: -16.3M Q4 '24: -13.9M Q1 '25: -13.6M Q4 '25: -20.4M Q1 '26: -19.7M Q2 '26: -21.3M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 40K 80K 120K Q4 '22: 113.2K Q4 '22

Operating Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q3 '21: -1.4M Q4 '21: -3.2M Q1 '22: -5.3M Q2 '22: -7.2M Q3 '22: -11.9M Q4 '22: -14.6M Q1 '23: -15.2M Q2 '23: -15.9M Q3 '23: -13.9M Q4 '23: -12.8M Q1 '24: -13.9M Q2 '24: -14.9M Q3 '24: -14.8M Q4 '24: -13.9M Q1 '25: -12.7M Q2 '25: -12.5M Q3 '25: -12.3M Q4 '25: -15.2M Q1 '26: -16.9M Q2 '26: -17.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q3 '22: -11.9M Q4 '22: -14.7M Q1 '23: -15.4M Q2 '23: -16.1M Q3 '23: -14.1M Q4 '23: -12.8M Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '21: 8M Q2 '21: 8.3M Q3 '21: 9M Q1 '22: 23M Q2 '22: 23.4M Q3 '22: 26.5M Q1 '23: 1.3M Q2 '23: 1.3M Q3 '23: 1.3M Q1 '24: 1M Q2 '24: 1M Q3 '24: 1M Q1 '25: 2.2M Q2 '25: 5.6M Q3 '25: 7.4M Q1 '26: 24.3M Q2 '26: 32.1M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q4 '21: -0.21 Q2 '24: -7.81 Q3 '24: -10.68 Q4 '24: -12.69 Q1 '25: -10.60 Q2 '25: -7.55 Q3 '25: -5.09 Q4 '25: -3.57 Q1 '26: -2.08 Q2 '26: -1.58 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.